One of the things that struck me at this year’s ESMO conference was the sheer variety and richness…
A deep dive into the phase 2 COAST study, along with some expert anecdotes
Developmental Therapeutics is hard, how do companies go about finding a way forward?
A look at the controversial adagrasib data in mCRC at ESMO21
A practice changing trial of note at ESMO21
A hard look at some IO agents in early development at ESMO21
Key posters of interest at ESMO21
What are Gritstone up to behind the scenes and where are they headed in the near-term?
